After a post-doctorate at the Lille Pasteur Institute, Olivier Barbier joined the Faculty of Pharmacy of Laval University and the CHU de Québec Research Center (endocrinology and nephrology axis) where he currently serves as full professor and independent scientist. With the invaluable assistance of his research professionals Mélanie Verreault and Jocelyn Trottier, Dr. Barbier has developed the laboratory of molecular pharmacology of the CHU de Québec Research Center. His research program aims at deciphering the bile acid signalling pathways in order to take advantage of their therapeutic potential in clinic. Research progresses of the last decades have revealed that these acids are not just cholesterol metabolites involved in fatty acid digestion, but play also a major role in controlling numerous biological functions such as glycaemia, inflammation and cell proliferation. Actually, the discovery of bile acid sensors (nuclear and membrane receptors) evidenced the role for these molecules as endo-, para- and intracrine hormones. In particular, these works lead to the approval by the FDA (2016) and Health Canada (2017) of the first synthetic bile acid (Ocaliva® or obeticholic acid, OCA) for the treatment of primary biliary cholangitis. In such an exciting context, researches of Barbier’s lab are focussing on 2 main subjects: auto-immune hepatobiliary diseases and prostate cancer.

Auto-immune hepatobiliary diseases (PBC et PSC)

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two rare diseases characterized by a reduction of bile flow and an accumulation of toxic bile acids in hepatic cells. This accumulation leads to chronic inflammation and to the destruction of liver cells. Dr. Barbier’s works aims at identifying new pharmaco-nutritional approaches (drug+nutrition treatment) providing a tight control of bile acid detoxification and, by so allowing a delay in diseases progression.

Prostate cancer

Prostate cancer mortality still represents 10% of Canadian death by cancer in 2017. The androgen receptor (AR) plays a critical role in the cancer progression, as well as in the development resistance to chemical castration, the first-line therapy for metastatic cancers. Members of the lab have observed that obeticholic acid (OCA) causes a near-complete inhibition of AR expression and activity in prostate cancer cell models. Dr. Barbier’s team currently works at developing this major discovery in order to bring it to patient’s bedside.

Excellence of Dr. Barbier’s work has been acknowledged by the reception of various prestigious awards (Association of Faculties of Pharmacy of Canada, Heart and Stroke Foundation – Québec, Pfizer Cardiovascular…), and by the publication of numerous peer-reviewed papers. He acts as a member of editorial board such as Drug Metabolism Review, PLoS One, The Canadian Journal of Gastroenterology and Hepatology. Besides his professor-researcher’s activities, Dr. Barbier also occupies important functions with institutional (University Council, Committee of Students Affairs of Laval University), provincial (Club de Recherche Clinique du Québec), national (Intern reviewer for the Canadian Institute of Health Research) and international authorities (Committee director of the Cholestatic and Biliary Disorders Special Interest Group, American Association for the Study of Liver Diseases).

CHUL
2705, boulevard Laurier
R-4701.7
Québec, Québec
Canada G1V 4G2
CHUL
2705, boulevard Laurier
R-4720
Québec, Québec
Canada G1V 4G2

89 entries « 1 of 18 »

Martinez T, Duron S, Schaal JV, Baudoin Y, Barbier O, Daban JL, Boutonnet M, Ausset S, Pasquier P

Tourniquet Training Program Assessed by a New Performance Score.

Journal Article

Prehosp Disaster Med, 33 (5), pp. 519-525, 2018, ISSN: 1049-023X.

Abstract | Links:

Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P

Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.

Journal Article

J Gastrointestin Liver Dis, 27 (3), pp. 273-279, 2018, ISSN: 1841-8724.

Abstract | Links:

Anhe FF, Nachbar RT, Varin TV, Trottier J, Dudonne S, Le Barz M, Feutry P, Pilon G, Barbier O, Desjardins Y, Roy D, Marette A

Treatment with camu camu (Myrciaria dubia) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice.

Journal Article

Gut, 2018, ISSN: 0017-5749.

Abstract | Links:

Anhe FF, Varin TV, Le Barz M, Pilon G, Dudonne S, Trottier J, St-Pierre P, Harris CS, Lucas M, Lemire M, Dewailly E, Barbier O, Desjardins Y, Roy D, Marette A

Arctic berry extracts target the gut-liver axis to alleviate metabolic endotoxaemia, insulin resistance and hepatic steatosis in diet-induced obese mice.

Journal Article

Diabetologia, 61 (4), pp. 919-931, 2018, ISSN: 0012-186X.

Abstract | Links:

Perreault M, Wunsch E, Bialek A, Trottier J, Verreault M, Caron P, Poirier GG, Milkiewicz P, Barbier O

Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions.

Journal Article

Can J Gastroenterol Hepatol, 2018 , pp. 8096314, 2018.

Abstract | Links:

89 entries « 1 of 18 »

Active projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Therapeutic potential of obeticholic acid for the treatment of advanced prostate cancer, Subvention, Instituts de recherche en santé du Canada, Volet Projet: Concours pilotes, from 2016-07-01 to 2020-06-30

Recently finished projects

  • 3.8 Deciphering host-microbial interactions for cardiometabolic and mental health disorders with novel multimodal light-based sensing tools, Subvention, Secrétariat des programmes interorganismes à l’intention des établissements, Fonds d'excellence en recherche Apogée Canada, from 2016-04-01 to 2018-03-31
  • Coupling metabolomic and proteomic approaches in profiling endobiotics metabolism, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2012-04-01 to 2017-03-31
  • Human and Microbial Integrative Genomics, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds de l'avant-garde (FA), from 2012-09-01 to 2016-08-31
  • Potentiel thérapeutique de l'acide obéticholique., Subvention, Fondation du CHU de Québec, from 2016-04-01 to 2017-03-31
Data provided by the Université Laval research projects registery